Academic Journal
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis
| العنوان: | Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis |
|---|---|
| المؤلفون: | Feng, KY, Li, J, Ianus, J, De Zeeuw, D, Fulcher, GR, Pfeifer, M, Matthews, DR, Jardine, MJ, Perkovic, V, Neal, B, Mahaffey, KW |
| المصدر: | 2715 ; 2707 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2021 |
| المجموعة: | Imperial College London: Spiral |
| مصطلحات موضوعية: | Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, canagliflozin, cardiovascular outcomes, hospitalization, SGLT2 inhibitor, type 2 diabetes, CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT, BASE-LINE CHARACTERISTICS, RISK, EMPAGLIFLOZIN, RATIONALE, MORTALITY, DISEASE, DESIGN, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors |
| الوصف: | Aim To determine the reasons for hospitalizations in the CANagliflozin cardioVascular Assessment Study (CANVAS) programme and the effects of the sodium-glucose co-transporter-2 inhibitor canagliflozin on hospitalization. Materials and Methods A secondary analysis was performed on the CANVAS programme that included 10 142 participants with type 2 diabetes randomized to canagliflozin or placebo. The primary outcome was the rate of total (first plus all recurrent) all-cause hospitalizations (ACH). Secondary outcomes were total hospitalizations categorized by the Medical Dictionary for Regulatory Activities hierarchy at the system organ class level, reported by investigators at each centre. Outcomes were assessed using negative binomial models. Results Of the 7115 hospitalizations reported, the most common reasons were cardiac disorders (23.7%), infections and infestations (15.0%), and nervous system disorders (9.0%). The rate of total ACH was lower in the canagliflozin group (n = 5795) compared with the placebo group (n = 4347): 197.9 versus 215.8 participants per 1000 patient-years, respectively (rate ratio [RR] 0.92; 95% confidence interval [CI] 0.86, 0.98). Canagliflozin reduced the rate of total hospitalizations because of cardiac disorders (RR 0.81; 95% CI 0.75, 0.88). There was no significant difference between the canagliflozin and placebo groups in the rates of total hospitalizations because of infections and infestations (RR 0.96; 95% CI 0.86, 1.02) or nervous system disorders (RR 0.96; 95% CI 0.88, 1.05). Conclusions In the CANVAS programme, the most common reasons for hospitalization were cardiac disorders, infections and infestations, and nervous system disorders. Canagliflozin, compared with placebo, reduced the rate of total ACH. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1462-8902 |
| Relation: | Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics; http://hdl.handle.net/10044/1/94091 |
| DOI: | 10.1111/dom.14525 |
| الاتاحة: | http://hdl.handle.net/10044/1/94091 https://doi.org/10.1111/dom.14525 |
| Rights: | © 2021 John Wiley & Sons Ltd. This is the accepted version of the following article: Feng, KY, Li, JW, Ianus, J, et al. Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. Diabetes Obes Metab. 2021; 23( 12): 2707- 2715, which has been published in final form at https://doi.org/10.1111/dom.14525 |
| رقم الانضمام: | edsbas.3D27388F |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.3D27388F 849 3 Academic Journal academicJournal 848.9462890625 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.3D27388F&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => http://hdl.handle.net/10044/1/94091# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Feng%2C+KY%22">Feng, KY</searchLink><br /><searchLink fieldCode="AR" term="%22Li%2C+J%22">Li, J</searchLink><br /><searchLink fieldCode="AR" term="%22Ianus%2C+J%22">Ianus, J</searchLink><br /><searchLink fieldCode="AR" term="%22De+Zeeuw%2C+D%22">De Zeeuw, D</searchLink><br /><searchLink fieldCode="AR" term="%22Fulcher%2C+GR%22">Fulcher, GR</searchLink><br /><searchLink fieldCode="AR" term="%22Pfeifer%2C+M%22">Pfeifer, M</searchLink><br /><searchLink fieldCode="AR" term="%22Matthews%2C+DR%22">Matthews, DR</searchLink><br /><searchLink fieldCode="AR" term="%22Jardine%2C+MJ%22">Jardine, MJ</searchLink><br /><searchLink fieldCode="AR" term="%22Perkovic%2C+V%22">Perkovic, V</searchLink><br /><searchLink fieldCode="AR" term="%22Neal%2C+B%22">Neal, B</searchLink><br /><searchLink fieldCode="AR" term="%22Mahaffey%2C+KW%22">Mahaffey, KW</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => 2715 ; 2707 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Wiley ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Imperial College London: Spiral ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Science+%26+Technology%22">Science & Technology</searchLink><br /><searchLink fieldCode="DE" term="%22Life+Sciences+%26+Biomedicine%22">Life Sciences & Biomedicine</searchLink><br /><searchLink fieldCode="DE" term="%22Endocrinology+%26+Metabolism%22">Endocrinology & Metabolism</searchLink><br /><searchLink fieldCode="DE" term="%22canagliflozin%22">canagliflozin</searchLink><br /><searchLink fieldCode="DE" term="%22cardiovascular+outcomes%22">cardiovascular outcomes</searchLink><br /><searchLink fieldCode="DE" term="%22hospitalization%22">hospitalization</searchLink><br /><searchLink fieldCode="DE" term="%22SGLT2+inhibitor%22">SGLT2 inhibitor</searchLink><br /><searchLink fieldCode="DE" term="%22type+2+diabetes%22">type 2 diabetes</searchLink><br /><searchLink fieldCode="DE" term="%22CANAGLIFLOZIN+CARDIOVASCULAR+ASSESSMENT%22">CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT</searchLink><br /><searchLink fieldCode="DE" term="%22BASE-LINE+CHARACTERISTICS%22">BASE-LINE CHARACTERISTICS</searchLink><br /><searchLink fieldCode="DE" term="%22RISK%22">RISK</searchLink><br /><searchLink fieldCode="DE" term="%22EMPAGLIFLOZIN%22">EMPAGLIFLOZIN</searchLink><br /><searchLink fieldCode="DE" term="%22RATIONALE%22">RATIONALE</searchLink><br /><searchLink fieldCode="DE" term="%22MORTALITY%22">MORTALITY</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE%22">DISEASE</searchLink><br /><searchLink fieldCode="DE" term="%22DESIGN%22">DESIGN</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiovascular+System%22">Cardiovascular System</searchLink><br /><searchLink fieldCode="DE" term="%22Diabetes+Mellitus%22">Diabetes Mellitus</searchLink><br /><searchLink fieldCode="DE" term="%22Type+2%22">Type 2</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Hypoglycemic+Agents%22">Hypoglycemic Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Sodium-Glucose+Transporter+2+Inhibitors%22">Sodium-Glucose Transporter 2 Inhibitors</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Aim To determine the reasons for hospitalizations in the CANagliflozin cardioVascular Assessment Study (CANVAS) programme and the effects of the sodium-glucose co-transporter-2 inhibitor canagliflozin on hospitalization. Materials and Methods A secondary analysis was performed on the CANVAS programme that included 10 142 participants with type 2 diabetes randomized to canagliflozin or placebo. The primary outcome was the rate of total (first plus all recurrent) all-cause hospitalizations (ACH). Secondary outcomes were total hospitalizations categorized by the Medical Dictionary for Regulatory Activities hierarchy at the system organ class level, reported by investigators at each centre. Outcomes were assessed using negative binomial models. Results Of the 7115 hospitalizations reported, the most common reasons were cardiac disorders (23.7%), infections and infestations (15.0%), and nervous system disorders (9.0%). The rate of total ACH was lower in the canagliflozin group (n = 5795) compared with the placebo group (n = 4347): 197.9 versus 215.8 participants per 1000 patient-years, respectively (rate ratio [RR] 0.92; 95% confidence interval [CI] 0.86, 0.98). Canagliflozin reduced the rate of total hospitalizations because of cardiac disorders (RR 0.81; 95% CI 0.75, 0.88). There was no significant difference between the canagliflozin and placebo groups in the rates of total hospitalizations because of infections and infestations (RR 0.96; 95% CI 0.86, 1.02) or nervous system disorders (RR 0.96; 95% CI 0.88, 1.05). Conclusions In the CANVAS programme, the most common reasons for hospitalization were cardiac disorders, infections and infestations, and nervous system disorders. Canagliflozin, compared with placebo, reduced the rate of total ACH. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1462-8902 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics; http://hdl.handle.net/10044/1/94091 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1111/dom.14525 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => http://hdl.handle.net/10044/1/94091<br />https://doi.org/10.1111/dom.14525 ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => © 2021 John Wiley & Sons Ltd. This is the accepted version of the following article: Feng, KY, Li, JW, Ianus, J, et al. Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis. Diabetes Obes Metab. 2021; 23( 12): 2707- 2715, which has been published in final form at https://doi.org/10.1111/dom.14525 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.3D27388F ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1111/dom.14525
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Science & Technology
[Type] => general
)
[1] => Array
(
[SubjectFull] => Life Sciences & Biomedicine
[Type] => general
)
[2] => Array
(
[SubjectFull] => Endocrinology & Metabolism
[Type] => general
)
[3] => Array
(
[SubjectFull] => canagliflozin
[Type] => general
)
[4] => Array
(
[SubjectFull] => cardiovascular outcomes
[Type] => general
)
[5] => Array
(
[SubjectFull] => hospitalization
[Type] => general
)
[6] => Array
(
[SubjectFull] => SGLT2 inhibitor
[Type] => general
)
[7] => Array
(
[SubjectFull] => type 2 diabetes
[Type] => general
)
[8] => Array
(
[SubjectFull] => CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT
[Type] => general
)
[9] => Array
(
[SubjectFull] => BASE-LINE CHARACTERISTICS
[Type] => general
)
[10] => Array
(
[SubjectFull] => RISK
[Type] => general
)
[11] => Array
(
[SubjectFull] => EMPAGLIFLOZIN
[Type] => general
)
[12] => Array
(
[SubjectFull] => RATIONALE
[Type] => general
)
[13] => Array
(
[SubjectFull] => MORTALITY
[Type] => general
)
[14] => Array
(
[SubjectFull] => DISEASE
[Type] => general
)
[15] => Array
(
[SubjectFull] => DESIGN
[Type] => general
)
[16] => Array
(
[SubjectFull] => Cardiovascular System
[Type] => general
)
[17] => Array
(
[SubjectFull] => Diabetes Mellitus
[Type] => general
)
[18] => Array
(
[SubjectFull] => Type 2
[Type] => general
)
[19] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[20] => Array
(
[SubjectFull] => Hypoglycemic Agents
[Type] => general
)
[21] => Array
(
[SubjectFull] => Sodium-Glucose Transporter 2 Inhibitors
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Feng, KY
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Li, J
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ianus, J
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => De Zeeuw, D
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fulcher, GR
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pfeifer, M
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Matthews, DR
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jardine, MJ
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Perkovic, V
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Neal, B
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mahaffey, KW
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2021
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 14628902
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => 2715 ; 2707
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |